|
BMS is looking to Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy to drive growth into the 2030s.
|
 |
|
The FDA’s decision is based on results from the Phase III ADVANCE-1 and ACCORD-2 studies.
|
|
|
The agreement is set to expand LEO Pharma’s pipeline in rare dermatology.
|
|
|
With $14.bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
|
|
|
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.
|
|
